150234-52-9

Basic information

• Product Name: (ASN670,LEU671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-675)
• Synonyms: (Asn670,Leu671)-APP770 (667-675), APP770 (667-675) Swedish Mutation;SER-GLU-VAL-ASN-LEU-ASP-ALA-GLU-PHE;H-SER-GLU-VAL-ASN-LEU-ASP-ALA-GLU-PHE-OH;(ASN670,LEU671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-675);(ASN670,LEU671)-APP770 (667-675);[Asn670,Leu671]-Amyloid β/A4 Protein Precursor770 (667-675)
• CAS NO: 150234-52-9
• Molecular Formula: C44H66N10O18
• Molecular Weight: 1023.05
• Mol File: 150234-52-9.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 1572.2±65.0 °C(Predicted)
• Appearance: /
• Density: 1.366±0.06 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 3.48±0.10(Predicted)
• CAS DataBase Reference: (ASN670,LEU671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-675)(CAS DataBase Reference)
• NIST Chemistry Reference: (ASN670,LEU671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-675)(150234-52-9)
• EPA Substance Registry System: (ASN670,LEU671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-675)(150234-52-9)

Safety Data

• Hazardous Substances Data: 150234-52-9(Hazardous Substances Data)

Usage

Description

(ASN670,LEU671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-675) is a specific sequence of amino acids within the amyloid beta precursor protein, which plays a crucial role in the formation of amyloid plaques associated with Alzheimer's disease. This sequence includes asparagine at position 670, leucine at position 671, and other amino acids such as alanine, serine, asparagine, valine, lysine, and glycine. The aggregation of amyloid beta peptides, including the (ASN670,LEU671) sequence, leads to the development of amyloid plaques and subsequent neurodegeneration in Alzheimer's disease. Targeting this specific sequence may provide potential therapeutic opportunities for treating the disease.

Uses

Used in Pharmaceutical Industry:
(ASN670,LEU671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-675) is used as a target for the development of therapeutic agents for Alzheimer's disease. The specific sequence is involved in the formation of amyloid plaques, which are a hallmark of the disease. By targeting this sequence, researchers aim to inhibit the aggregation of amyloid beta peptides and prevent the formation of plaques, thereby potentially slowing down or halting the progression of neurodegeneration in Alzheimer's patients.
Used in Research and Development:
(ASN670,LEU671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-675) is used as a subject of study in research aimed at understanding the molecular mechanisms underlying Alzheimer's disease. Investigating the role of this specific sequence in amyloid plaque formation can provide valuable insights into the pathogenesis of the disease and help identify potential therapeutic targets. Additionally, this sequence can be used in the development of diagnostic tools and biomarkers for early detection and monitoring of Alzheimer's disease progression.
Used in Drug Delivery Systems:
(ASN670,LEU671)-AMYLOID BETA/A4 PROTEIN PRECURSOR770 (667-675) can be employed in the design of novel drug delivery systems to enhance the efficacy of therapeutic agents targeting Alzheimer's disease. By incorporating this specific sequence into drug delivery platforms, researchers can potentially improve the delivery, bioavailability, and therapeutic outcomes of drugs aimed at inhibiting amyloid plaque formation and neurodegeneration.